Chapter 3. Drug-Associated Mitochondrial Toxicity

  1. James A. Dykens2,
  2. Yvonne Will3
  1. Rhea Mehta,
  2. Katie Chan,
  3. Owen Lee,
  4. Shahrzad Tafazoli,
  5. Peter J. O'Brien

Published Online: 22 JAN 2008

DOI: 10.1002/9780470372531.ch3

Book Title

Drug-Induced Mitochondrial Dysfunction

Drug-Induced Mitochondrial Dysfunction

Additional Information

How to Cite

Mehta, R., Chan, K., Lee, O., Tafazoli, S. and O'Brien, P. J. (2008) Drug-Associated Mitochondrial Toxicity, in Drug-Induced Mitochondrial Dysfunction (eds J. A. Dykens and Y. Will), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470372531.ch3

Editor Information

  1. 2

    Pfizer, Inc., Sandwich, UK

  2. 3

    Pfizer, Inc., Groton, Connecticut, USA

Author Information

  1. Graduate Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada

Publication History

  1. Published Online: 22 JAN 2008
  2. Published Print: 14 SEP 2008

ISBN Information

Print ISBN: 9780470111314

Online ISBN: 9780470372531

SEARCH

CHAPTER TOOLS

Get PDF (821K)

Keywords:

  • drug-associated mitochondrial toxicity;
  • drug-induced hepatic cholestatic injury;
  • membrane-interaction QSAR analysis

Summary

This chapter contains sections titled:

  • Introduction

  • Drug-induced fatty liver (microvesicular steatosis) and steatohepatitis: endogenous lipotoxins

  • Drug-induced hepatic cholestatic injury

  • Drug-induced oxidative stress and tissue toxicity: endogenous or exogenous reactive oxygen species toxins

  • Structure–activity relationships

  • Conclusions

  • References

Get PDF (821K)